Logo

AbbVie Presents New Post-Hoc Analyses of Rinvoq (upadacitinib) in P-III SELECT-PsA 1 & 2 trials for Active Psoriatic Arthritis at ACR 2021

Share this

AbbVie Presents New Post-Hoc Analyses of Rinvoq (upadacitinib) in P-III SELECT-PsA 1 & 2 trials for Active Psoriatic Arthritis at ACR 2021

Shots:

  • The P-III SELECT-PsA 1 & 2 trials evaluate Rinvoq (15/30mg) vs PBO in patients with active PsA & axial involvement who have a history of intolerance or inadequate response to one non-biologic & biologic DMARD
  • The results showed a greater clinical response related to axial across both studies compared to Humira across all BASDAI & ASDAS EPs in SELECT-PsA 1 @24wks. & proportion of patients achieve ASDAS CII (69.8% vs 54.1%). The safety profile was consistent with previously reported studies & no new safety risks were observed
  • Rinvoq (15mg) has received the US FDA’s approval for RA & EC’s approval for RA, PsA & AS. The therapy has received EC’s approval for 15 & 30mg doses to treat AD

  Ref: PR Newswire | Image: abbvie

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions